| |
|
|
🔬 The Code Breakers |
Inside the Longevity Frontier |
|
|
|
| |
|
| |
In Today's Edition |
Today's issue is about cracking open biology's most stubborn locks — from the genes of an almost-immortal rodent to the misfolded proteins behind Alzheimer's. |
Here's what caught our attention: |
→ Scientists borrowed a gene from the world's longest-lived rodent — and it made mice live longer and resist cancer |
|
|
→ A daily pill that attacks four Alzheimer's proteins at once — just published its results in Nature |
|
|
→ Eli Lilly just placed its biggest bet ever on AI-designed drugs — $2.75 billion to Insilico Medicine |
|
|
→ A Nobel Prize winner's startup can now silence your "bad cholesterol" gene — without changing your DNA |
|
|
→ One injection of lab-grown retinal cells — and patients are reading better three years later |
|
|
→ Your mitochondria have their own DNA, and when it mutates — a $2.8 million NIH study wants to know if exercise can fix it |
|
|
↓ KEEP READING |
|
|
|
| |
|
|
|
|
|
| |
A Longevity Gene From the Naked Mole Rat Now Works in Mice |
Naked mole rats live about ten times longer than other rodents their size. Scientists at the University of Rochester just figured out why — and proved they can transfer that advantage. They moved a gene responsible for producing high molecular weight hyaluronic acid into mice, and the mice lived longer and healthier. |
Key Points |
The gene boosts production of a substance called HMW-HA, which is unusually abundant in naked mole rats. It appears to protect against cancer, reduce chronic inflammation, and support healthier guts. Think of it as a molecular shield that naked mole rats evolved over millions of years. The modified mice showed an approximate 4.4% increase in median lifespan. That sounds modest, but it also came with stronger cancer resistance, less inflammation, and better gut health. The researchers say this is the first time a longevity trait from one mammal has been successfully exported to another. It took the team ten years to go from discovering HMW-HA in the naked mole rat to proving it works in mice. Lead researcher Vera Gorbunova calls it "proof of principle" — nature's longest-lived species may contain biological tools we can adapt for human benefit.
|
|
|
|
|
| |
Why It Matters: This isn't a drug or a supplement. It's a proof of concept that longevity traits can move between species. That idea was theoretical until yesterday. We're not close to gene therapy for aging in humans — but we now know the door is open. If researchers can figure out which of nature's longevity tricks are transferable, the catalog of potential interventions gets much larger. Worth keeping an eye on Rochester's work. |
|
|
|
|
SOURCE · SCIENCE DAILY · UNIVERSITY OF ROCHESTER |
|
|
|
|
|
|
| |
|
|
|
| |
An Alzheimer's Pill That Hits Four Toxic Proteins at Once |
For decades, Alzheimer's drugs have aimed at one target: amyloid. Most have failed. Annovis Bio just published Phase 2/3 results for buntanetap, a daily oral pill that blocks production of four neurotoxic proteins simultaneously — amyloid, tau, alpha-synuclein, and TDP-43. The results, published in Nature NPJ Dementia, show it works. |
Key Points |
Buntanetap works by targeting the RNA machinery that tells your cells to make these toxic proteins. Instead of cleaning up the mess after it forms, it reduces production at the source. It's an oral tablet — no infusions, no hospital visits. In the trial of 351 patients, the 30 mg dose produced statistically significant improvements in cognition (p=0.015) among patients with mild Alzheimer's confirmed by pTau217 biomarkers. The drug also reduced markers of brain inflammation and neurodegeneration, including neurofilament light chain. The drug was well tolerated even in ApoE4 carriers — the group at highest genetic risk for Alzheimer's. Annovis is now 80% enrolled in a pivotal Phase 3 trial of 760 patients. The first readout is expected in early 2027.
|
|
|
|
|
| |
Why It Matters: Most of us know someone with Alzheimer's. The current approved drugs target only amyloid and require IV infusions. Buntanetap attacks the problem from a different angle — and you take it as a pill. If the Phase 3 trial confirms these results, it could change how we treat neurodegeneration. We don't know yet if it will. But the multi-target approach is worth our attention. Ask your neurologist about the ANVS trial if a family member has early-stage symptoms. |
|
|
|
|
SOURCE · GLOBENEWSWIRE / NATURE NPJ DEMENTIA · ANNOVIS BIO PHASE 2/3 PUBLICATION |
|
|
|
|
|
|
| |
|
|
|
| |
Eli Lilly Bets $2.75 Billion That AI Can Design Better Drugs |
On March 29, Eli Lilly signed its biggest AI deal ever — a $2.75 billion collaboration with Hong Kong-based Insilico Medicine. Lilly gets an exclusive license to develop and commercialize a portfolio of AI-designed oral drugs. Insilico gets $115 million up front, with the rest tied to milestones and royalties. |
Key Points |
Insilico's AI platform doesn't just screen existing chemical libraries faster. It designs entirely new molecules from scratch. Their system has produced 28 drug candidates, with nearly half already in clinical trials. Their first compound went from target identification to Phase 1 in under 30 months. Traditional pharma averages four to six years for the same step. This isn't Lilly's first bet on Insilico. The two companies have worked together since 2023 and signed a $100 million deal in November 2025. This latest agreement is a tenfold escalation. The CEO of Insilico, Alex Zhavoronkov, said Lilly's internal AI capabilities are stronger than almost anyone else's in the industry. Across the industry, AI-designed drugs are clearing Phase 1 trials at 80–90% success rates. Historically, that number has been 40–65%. The real test comes in Phase 3 — and we're only now starting to see AI drugs reach that stage. We'll know much more by year's end.
|
|
|
|
|
| |
Why It Matters: When the biggest pharma company in the world writes a check this size for AI, it tells us something about where drug development is headed. The implication for longevity is direct — faster discovery means age-related diseases get targeted sooner. We're cautiously optimistic. The early data is strong. But no AI-designed drug has been fully approved yet. Watch the Phase 3 results coming later this year. |
|
|
|
|
SOURCE · BIOPHARMA DIVE / STAT NEWS · LILLY-INSILICO COLLABORATION |
|
|
|
|
|
|
| |
|
|
|
| |
A One-Time CRISPR Shot to Silence Your "Bad Cholesterol" Gene |
High LDL cholesterol is one of the leading killers of older adults. Right now, most people manage it with daily statins. But a company co-founded by Nobel laureate Jennifer Doudna is presenting data today on something different — STX-1150, a single-dose gene therapy that silences the PCSK9 gene responsible for high LDL, without permanently altering your DNA. |
Key Points |
Scribe Therapeutics engineered a custom CRISPR system they call ELXR — Epigenetic Long-Term X-Repressor. Instead of cutting your DNA (like older CRISPR tools), it adds chemical tags that tell the PCSK9 gene to stay quiet. The gene is still there, intact. It just stops making the protein that raises LDL. Scribe is presenting preclinical data at two major conferences starting today: ASGCT in Boston (May 11–15) and EAS in Athens later this month. They also unveiled DeepXE, an AI platform that predicts CRISPR editing efficiency before going to the lab. Scribe has deals with both Sanofi and Eli Lilly. The idea of treating cholesterol with a single shot instead of daily pills has been pursued by several companies. What sets Scribe apart is the epigenetic approach — it's potentially reversible, which matters for safety. If something goes wrong, the gene hasn't been permanently edited.
|
|
|
|
|
| |
Why It Matters: Imagine never needing to refill a statin prescription again. One injection, and your body stops overproducing the protein that drives LDL cholesterol. We're not there yet — this is still preclinical. But the approach is elegant: it treats the root cause without permanent changes to your genome. If you're on a statin and watching this space, the next two years of data from Scribe will tell us whether this becomes real. |
|
|
|
|
SOURCE · SCRIBE THERAPEUTICS / BIOSPACE · ASGCT & EAS 2026 PRESENTATIONS |
|
|
|
|
|
|
| |
|
|
|
| |
One Injection of Lab-Grown Retinal Cells — and Vision Keeps Improving Three Years Later |
Age-related macular degeneration steals the central vision of millions of older adults. It's been considered irreversible. But Lineage Cell Therapeutics just presented 36-month data showing that a single injection of lab-grown retinal pigment epithelial cells can restore visual acuity — and the gains are still holding at three years. |
Key Points |
The therapy, called RG6501 (OpRegen), involves transplanting "off the shelf" human retinal cells beneath the damaged retina. These cells replace the ones lost to geographic atrophy — the advanced dry form of macular degeneration that currently has no cure that restores vision. Among patients who received extensive cell coverage of their lesion area, visual acuity improved by an average of 9 letters on the standard eye chart at 36 months. OCT imaging confirmed actual structural recovery — the retinal pigment layer was regrowing, and there were signs of photoreceptor recovery. This is a single administration. No repeat injections. Roche and Genentech are partners on the program, and a Phase 2a study (GAlette) is now enrolling to optimize delivery. The data were presented at the Foundation Fighting Blindness Retinal Innovation Summit last week.
|
|
|
|
|
| |
Why It Matters: Geographic atrophy affects roughly 5 million people worldwide, and most are over 60. Until now, the best we could do was slow the damage. This data suggests we might be able to reverse it. The idea that a one-time cell transplant can restore vision and hold for three years challenges the assumption that retinal damage is permanent. If you or someone you love has dry AMD, ask your ophthalmologist about the GAlette trial. |
|
|
|
|
SOURCE · LINEAGE CELL THERAPEUTICS / PHARMIWEB · FFB RETINAL INNOVATION SUMMIT |
|
|
|
|
|
|
| |
|
|
|
| |
A $2.8 Million Study Is Asking: Can Exercise Fix Your Mutating Mitochondria? |
Your mitochondria — the tiny power plants inside every cell — carry their own separate DNA. When that DNA mutates, your cells produce less energy, inflammation rises, and aging accelerates. A new NIH-funded study at the University of Rhode Island is investigating whether exercise and calorie restriction can help your body clear those mutations before they pile up. |
Key Points |
Normally, an enzyme in your cells repairs or removes mitochondrial DNA mutations. But as you age, that editing process becomes less efficient. Mutations accumulate and spread. The result is what researchers call "mitochondrial dysfunction" — and it's been linked to neurodegeneration, cancer, cardiovascular disease, and metabolic syndrome. In preliminary work, the team found something striking: mice with mutated mitochondrial DNA that exercised regularly became nearly indistinguishable from healthy mice. Their muscles demanded more energy, which seemed to trigger a process that cleared out defective mitochondria and replaced them with healthy ones. The effect was real — but temporary. By 40 weeks, the disease caught up. The five-year, $2.8 million study will investigate exactly how different tissues accumulate and clear mitochondrial mutations, and whether the timing of intervention matters. The researchers want to understand why exercise helps but doesn't permanently fix the problem — and what would.
|
|
|
|
|
| |
Why It Matters: We all know exercise is good for us. This study might tell us exactly why at the cellular level — and whether there's a window of time when it matters most. If mitochondrial mutation clearance can be enhanced or extended, it opens a door to treatments that slow aging at its root. In the meantime, the early mouse data is one more reason not to skip your morning walk. |
|
|
|
|
SOURCE · UNIVERSITY OF RHODE ISLAND / PHYS.ORG · NIH-FUNDED STUDY |
|
|
|
|
|
|
| |
|
|
|
| |
| |
Six breakthroughs you won't see in mainstream media.
Thanks for reading NextWave — see you next time. |
— THE EDITORS // NEXTWAVE MARKETS |
|
|
|
| |
|
|
